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Relationship ofECL Cells and Gastric Neoplasia
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The enterochromaffin-like (ECL) cell in the oxyntic mucosa has a key role in
the regulation ofgastric secretion since it synthesizes and releases the histamine
regulating the acid secretion from the parietal cell. Gastrin is the main regulator
ofthe ECLcell function and growth. Long-term hypergastrinemia induces ECL
cell hyperplasia, and if continued, neoplasia. ECL cell carcinoids occur in man
after long-term hypergastrinemia in conditions like pernicious anemia and gas-
trinoma. There is also accumulating evidence that a proportion ofgastric carci-
nomas of the diffuse type is derived from the ECL cell. Furthermore, the ECL
cell may, by producing substances with angiogenic effects (histamine and basic
fibroblast growth factor), be particularly prone to develop malignant tumors.
Although the general opinion is that gastrin itselfhas adirect effect on the oxyntic
mucosal stem cell, it cannotbe excluded that the general trophic effect ofgastrin
on the oxyntic mucosa is mediated by histamine or other substances from the
ECL cell, and that the ECL cell, therefore, could play a role also in the tumori-
genesis/carcinogenesis ofgastric carcinomas of intestinal type.
INTRODUCTION
The enterochromaffin-like (ECL)b cell was identified in the oxyntic mucosa in the
sixties [1] and accepted as the cell producing and storing the histamine taking part in the
regulation ofgastric acid secretion in the rat [2]. Subsequently the ECLcell was described
in other species including man, but histamine was not found in the ECL cells in non-
murine species until the latter part ofthe eighties [3]. It was then shown that the stimulatory
effect of gastrin on acid secretion could be solely explained by stimulation of histamine
release from the ECL cell [4]. Histamine is released from the ECL cells at the base ofthe
glands to the capillaries, thereby reaching all the parietal cells in the same gland [4, 5].
Gastrin was soon recognized as an important stimulant of the ECL cell growth inducing
not only ECL cell hyperplasia, but also ECL-omas in the rat [6]. Moreover, the function
of the ECL cell (synthesis and release of histamine) showed the same concentration
response dependence to gastrin as did ECL cell proliferation [7], suggesting interaction
with the same receptor. However, based upon cloning ofthe gastrin receptor from purified
parietal cells, the gastrin receptor was claimed to be situated on the parietal cell [8]. The
presence of a gastrin receptor on the parietal cell has not been confirmed in functional
studies, whereas a gastrin receptor has been demonstrated functionally on ECL cells [9]
where gastrin receptor mRNAexpression also has been demonstrated [10]. It is, therefore,
indisputable that there is a gastrin receptor regulating the function as well as growth ofthe
ECL cell, whereas it is doubtful whether there is such a receptor on the parietal cell.
aTo whom all correspondence should be addressed: Helge L. Waldum, Department of Medicine,
University Hospital, N-7006Trondheim, Norway. Tel.: 47 73 99 85 41; Fax: 47 73 99 75 46; E-mail:
helge.waldum@medisin.ntnu.no.
bAbbreviations: ECL, enterochromaffin-like; CgA, chromogranin A; HDC, histidine decarboxylase;
bFGF, basic fibroblast growth factor; TGFa, transforming growth factor a; H2, histamine2; H,,his-
tamine,; MEN, multiple endocrine neoplasia.
325Waldum et al.: ECL cells and gastric neoplasia
ECL CELL FUNCTION
Gastrin stimulates the release ofhistamine from the ECLcell and at the same time the
synthesis of histamine at least partially by increasing histidine decarboxylase (HDC)
mRNAabundance [11]. Histamine release has been reported to be stimulated by cholinergic
agents [12], although the histamine releasing activity ofthese agents is at best marginal [13].
The ECLcell furthermore stores chromograninA(CgA), and gastrin seems to regulate
the release ofthe CgA split product pancreastatin and ofhistamine in the same way [14].
Calbindin [15] basic fibroblast growth factor (bFGF) [16], glycoprotein hormones [17],
and transforming growth factor a (TGFa) [18] have also been reported to be stored in the
ECL cell. The regulation ofthe release of these substances has not been clarified.
ECL CELL GROWTH REGULATION
Gastrin is the main regulator of ECL cell proliferation. Thus, hypergastrinemia
induces ECL cell hyperplasia [6], while hypogastrinemia reduces ECL cell proliferation
[19]. Accordingly, gastrin in physiological concentrations does affect ECLcell proliferation
and ECL cell density. However, prolonged hypergastrinemia inducing marked ECL cell
hyperplasia results in a normalization or even reduction ofthe ECL cell proliferation [20].
The apparent reduction in gastrin-stimulated ECLcell proliferation rate persists as long as
ECL cell hyperplasia lasts [20]. This suggests that the ECL cell itself produces a factor
inhibiting its own proliferation. Because the histamine2 (H2) antagonist loxtidine seems to
induce ECL cell carcinoids in more species than the proton pump inhibitor omeprazole
[21], we explored the effect ofhistamine on ECLcell proliferation. We found that the his-
tamine, (H1) antagonist astemizole tended to have a slight stimulatory effect on ECL cell
function and ECL cell proliferation [22], and the unsurmountable H2 receptor antagonist
loxtidine gave a slightly more pronounced increase in the density of argyrophilic cells
compared with omeprazole in spite of lower gastrin levels [21]. The effect of histamine
on ECL cell proliferation has also been studied by Modlin and co-workers [23]. They
found that the H1 antagonist cyproheptadine reduced ECL cell hyperplasia induced by
hypergastrinemia [23]. It can be concluded that the role of histamine as a regulator
(inhibitor) of ECL cell growth is not yet settled. However, the fact that the ECL cell pro-
liferation is reduced as long as ECL cell hyperplasia persists [20] indicates that the ECL
cells produce a factor reducing its own proliferation.
TUMORIGENIC FACTORS FROM THE ECL CELL
Vascular effects
Histamine has an angiogenic effect [24], which could be ofimportance in tumorigenesis.
Moreover, the effect ofhistamine on capillary permeability would promote passage ofcells
from the tissue into the blood stream and, thus, facilitate metastasis. bFGFproduced in the
ECL cell [16] has also an angiogenic effect [24]. Thus, substances normally produced in
the ECLcell facilitate tumorgrowth and metastases. This could be a general phenomenon
of neuroendocrine cells explaining the apparent discrepancy between the low degree of
cellular atypia and the clinically malignant behavior ofsuch tumors. In other words, these
cells may be more likely to develop tumors, including malignant ones, due to their normal
production ofparacrine factors. Therefore, tumors may arise from such cells after fewer
mutations and with less deviation from the normal cell than tumors from cells normally
lacking the production of such tumorigenic factors.
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Effects ofECL cellproducts on theproliferation ofother cells in gastric mucosa
Whereas it is now accepted that the stimulation ofacid secretion by gastrin is mediated
by the stimulation ofhistamine release [4], gastrin stimulatory effect on stem cell prolif-
eration in the oxyntic mucosa [25] is thought to be a direct effect ofgastrin. However, the
presence ofa gastrin receptor on the parietal cell [8] has not been confirmed, and it could
also be that the gastrin stimulatory effect on stem cell proliferation is a secondary one
(Figure 1). We have previously suggested that histamine could mediate also this effect of
gastrin [26], and we have given experimental arguments in favor of this view [21]. We
could not, however, find that the H2 agonist impromidine increased the stemcell proliferation
[27]. Anderson and co-workers furthermore showed thatthe general trophic effect ofgastrin
in the oxyntic mucosa was apparently not dependent on histamine since hypergastrinemia
in combination with the histidine decarboxylase inhibitor a-fluoromethyl histidine
induced an increase in the oxyntic mucosal thickness [28]. Later we could show that
although a-fluoromethyl histidine does reduce gastrin stimulated histamine release, it
does not abolish it [14]. Therefore, the general trophic effect of gastrin on the oxyntic
mucosa can nevertheless be mediated by histamine. As stated above, the ECL cell pro-
duces many different factors, and it is possible that some ofthese like bFGF [29] or hist-
amine [26, 30] could affect the proliferation ofthe stem cell. The localization ofthe ECL
cell at the base ofthe gastric glands makes it possible for substances to reach not only the
parietal cells, but also the stem cells, via the capillaries. It may, therefore, be concluded
that the ECL cell could play an important role not only in the regulation of the function,
but also the proliferation ofthe cells in the oxyntic mucosa.
TUMORS THATARISE OR MAYARISE FROM THE ECL CELL
It is accepted that murine neuroendocrine cells do proliferate, whereas it has been
stated that human gastrointestinal neuroendocrine cells do not [31]. The latter conclusion
l \ =C ~~~~Histamine and
() ) ~~~~~~othermediators
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Gastin
Figure 1. Products from the ECL cell can reach and affect the function ofthe parietal cell as
well as the proliferation ofthe endodermal stem cell by substances released to the capillaries.
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was obviously based on an insufficient number of cells studied [32], and taking into con-
sideration that gastrin induces hyperplasia and ECL-omas in man [33] as well as murine
species [6], it seems clear that also the human ECL cell does proliferate. The ECL cell,
being the most predominant neuroendocrine cell in the oxyntic mucosa [34], is the most
common origin of carcinoids arising in that tissue [35]. Moreover, hypergastrinemia pre-
disposes to the development of carcinoids in the oxyntic mucosa and more specifically to
ECL-omas whether there is anacidity/hypoacidity [36] or increased acid secretion [33]. It
has been claimed that hypergastrinemia alone is not sufficient to induce ECL-omas, and
that ECL-omas in patients with gastrinomas occur exclusively in patients with concomi-
tant multiple endocrine neoplasia (MEN) [33]. However, spontaneous gastrinoma may
also be accompanied by ECL-omas [35, 37], and ciprofibrate, a stimulator of peroxisome
proliferation, induces ECL-omas [38] without inhibiting gastric acid secretion [39].
Moreover, ciprofibrate influences the function of the D-cell in the antrum where it is of
the open type, but not in the oxyntic mucosa [40], suggesting that the ECL cells in ciprofi-
brate treated rats are influenced by hypergastrinemia alone. Therefore, hypergastrinemia
seems to be sufficient to induce ECL-omas, and it is presently impossible to decide
whether gastritis in the oxyntic mucosa plays a separate role in ECL cell tumorigenesis
[41]. This is, indeed, an important question since Helicobacter pylori (HP) infection
induces hypergastrinemia [42] and also predisposes to gastric malignancies [43]. ECL-
omas developing in patients with hypergastrinemia are more benign than those developing
without hypergastrinemia (so-called spontaneous ECL-omas) [35]. This is hardly surprising,
since hypergastrinemia will be expected to stimulate the proliferation not only of normal
ECL cells but also slightly modified ECL cells with a few mutations. ECL-omas occurring
without hypergastrinemia most probably have greater derangements in the growth control
indicating more mutations or mutations with more severe functional effects. There is no
reason to doubt that ECL-omas developing in normogastrinemic individuals are on an
average more malignant than those found in hypergastrinemic individuals [35], although
some of the latter ones also show malignant behavior both inthe rat [44] and man [35].
ECL cell hyperplasia secondary to hypergastrinemia in the rat [45] and in man [46] has
been reported to be reversible. It is, however, highly unlikely that all mutated cells will
disappear when normogastrinemia is restored. It is more likely that abolishing hypergas-
trinemia will only reduce the number of mutated as well as normal ECL cells. This view
is also supported by a study on Mastomys showing that ECL-omas developed in
Mastomys treated for 24 weeks with an inhibitor of gastric acid secretion and then
observed for 24 more weeks without any treatment [47]. Therefore, hypergastrinemia
obviously induces mutations in ECL cells since it alone leads to tumors including malignant
ones from that cell. Accordingly, even short-term hypergastrinemia may give a long-term
increased risk of ECL cell derived tumors.
As for other carcinoids, the fraction of tumor cells in ECL-omas demonstrating markers
specific for ECL cells or even neuroendocrine markers varies [35]. Rindi and co-workers,
in their retrospective study on 55 gastric tumors with previously established neuroen-
docrine nature, described 35 cases as related to hypergastrinemia and being relatively
benign although two of them metastasized. There were ten so-called sporadic ECL-omas,
most of them metastatic or locally invasive and, furthermore, nine so-called neuroen-
docrine carcinomas showing high mortality [35]. Whereas the ECL cell was accepted as
the cell of origin in the carcinoids, the neuroendocrine carcinomas (the distinction
between metastasizing carcinoids and neuroendocrine carcinomas, was not clearly given)
were claimed to be of proto endocrine nature and of possible endodermal origin [35].
However, although the secretory granules in these malignant cells were impossible to
classify due to their atypical appearance, some tumor cells were Grimelius positive (range
five to 80 percent) and serotonin negative [35]. Staining these tumors by the Sevier
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Munger method [48] may have classified also these tumors as ECL cell-derived [49].
Interestingly, they described a gland-like growth pattern both in the spontaneous ECL-
omas and the so-called neuroendocrine carcinomas [35]. It is, indeed, difficult to distin-
guish between neuroendocrine tumors and adenocarcinomas by lightmicroscopy alone, as
demonstrated in retrospective studies on human tumors [50], the reclassification of the
tumors developing in rats during life-long hypergastrinemia [44, 51], and the gastric
tumors of Mastomys [52, 53]. While Rindi et al. studied previously accepted neuroen-
docrine gastric tumors [35], we have re-examined gastric tumors previously classified as
adenocarcinomas [54]. We found that seven of 19 (36 percent) of tumors of diffuse type
and none of ten tumors of intestinal type (classified according to Lauren [55]) contained
Sevier Munger positive and diazo and serotonin negative tumor cells [54,56] compatible
with an ECL cell origin [49]. The fraction of tumor cells having staining qualities com-
patible with an ECL cell origin varied from less 0.5 percent to 10 percent [54]. However,
as there is a continuous reduction in the percentage ofrecognizable ECLcells in the more
typical ECL-omas [35], it is hardly logical to dismiss the ECL cell origin of tumors even
when only a few tumor cells show specific staining. In this context it should be recalled
that the diagnosis of adenocarcinoma is made upon glandular growth pattern and mucine
positivity. However, mucine positivity reflects only the presence ofglycoproteins, including
glycoprotein hormones [57] which are found in ECL cells [17]. Mucine positivity can,
therefore, hardly be regarded as a specific staining forexocrine cells. Furthermore, as pre-
viously discussed, glandular growth pattern may also be found in neuroendocrine tumors
[35, 58]. Therefore it may be concluded that the ECL cell could be the cell of origin not
only for most ofthe carcinoids localized to the oxyntic mucosa, but also for a proportion
of the tumors presently classified as adenocarcinomas. This may particularly be the case
for adenocarcinomas of the diffuse type. Although most patients with gastric carcinoma
do not have hypergastrinemia at the time ofdiagnosis, it cannot be excluded that previous
hypergastrinemia of shorter or longer duration could have contributed to the tumorigene-
sis. Moreover, gastrin receptors have been described on gastric carcinoma cell lines, and
interestingly only on cell lines derived from carcinomas ofthe diffuse type [59, 60].
Ifhypergastrinemia at one stage orthe otherplays an important role in the tumorigenesis
leading to gastric carcinomas ofthe diffuse type, such patients would be expected to have
higher gastrin values than those with tumors ofthe intestinal type [61]. This is, however,
notthe case [62] although there is areportdescribing highergastrin values inpatients with
diffuse type of gastric carcinoma [63]. However, the ECL cell is the only among seven
neuroendocrine cells in the oxyntic mucosa [64] where gastrin has a positive trophic
effect, whereas gastrin has a negative trophic effect on the oxyntic D-cell [65]. Thus, the
D-cell could play a role in the tumorigenesis in conditions with long-term hypogastrinemia
such as after gastric resection [66]. Therefore, due to the heterogeneity of the neuroen-
docrine cells, and the differences in the effect ofgastrin on these cells with regard to their
proliferation, attempts to correlate gastrin in blood and the occurrence of diffuse gastric
carcinomas may not disclose important relationships in subgroups of the patients.
Moreover, a correlation between type of gastric carcinoma and gastrin in blood should
only be assessed when studying tumors arising in the oxyntic mucosa since the ECL cell
is exclusively found in this area.
It should be realized that we [54] and others [50, 67] have found that neuroendocrine
carcinomas have been underestimated in the classification ofgastric carcinomas. Staren and
co-workers reclassified both tumors ofpoorly differentiated and moderately differentiated
adenocarcinomas toneuroendocrine carcinomas based uponhistochemical stainingqualities
of tumor cells [67]. Although neuroendocrine gastric carcinomas previously most often
have been misclassified as being gastric carcinomas ofthe diffuse type, they can, [67] like
carcinoids [58], show a glandular growthpattern and, therefore, be classified as carcinomas
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of intestinal type. Nevertheless, neuroendocrine differentiation in tumor cells is found
much more often in gastric carcinomas of the diffuse type compared with the intestinal
type [68]. Chejfec and Gould suggested as early as in 1977 that some undifferentiated gastric
carcinomas were derived from neuroendocrine cells [50], and in 1956 Waldenstr0m and
co-workers described apatient with amalignanttumorreleasing histamine secondary to food
intake, thus probably representing a malignant ECL-oma [69]. There are many observations
suggesting a fundamental biological difference between gastric carcinomas ofdiffuse and
intestinal type. Thus, tumors do not change from one type into the other in the individual
patient [55]; in epidemiological studies, intestinal but not diffuse gastric carcinomas show
a reduced incidence [70], and there is a difference in sensitivity towards cytotoxic drugs
between the two types of gastric carcinoma [71]. Interestingly, bFGF is detected and its
mRNA is expressed more often in gastric tumors of undifferentiated type compared with
differentiated ones, particularly in the scirrhous variant [72]. It should be recalled that
bFGF is produced in the normal ECL cell [16], and it might be that the well known fibrosis
in these carcinomas [73,74] is due to a factor like bFGF being released from a neuroen-
docrine tumor cell [75]. Fibrosis, locally [76] orremote from the tumor (like the valves of
the heart) [77], is a well known accompanying reaction to midgutcarcinoids. Some diffuse
carcinomas also induce ahyperplasia ofthecovering gastric mucosa [78]. Thesecarcinomas
often show endocrine differentiation, and interestingly most of them occur in young
women [78]. In that context it should be recalled that ECL cell carcinoids develop more
frequently in female than in male rats [6, 44]. Ooi and co-workers, however, described no
proliferative activity of tumor cells with neuroendocrine differentiation in gastric carci-
nomas [79]. An alternative interpretation oftheir finding is that the most rapidly dividing
tumor cells are the most dedifferentiated ones and, thus, the cells without specific markers
[80]. Therefore, there are many indications suggesting that at least apartofthe gastric car-
cinomas ofdiffuse type actually are neuroendocrine tumors (Figure 2).
Normal ECL cell
ECL cell hyperplasia
O'.s
Gastric carcinoma ofdiffuse type
Figure 2. The ECL cell may give rise to gastric carcinoids, neuroendocrine carcinomas and
possibly gastric carcinomas (mainly ofthe diffuse type).
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Gastric carcinoma ofintestinal type
Since the ECLcell is localized to the oxyntic mucosa only, this cell probably does not
influence the growth and, thereby, tumorigenesis in other parts of the stomach. Never-
theless, long-term treatment ofmice with potent and irreversible H2-antagonists has been
reported to induce not only tumors in the oxyntic mucosa but also in the forestomach [81].
The pathogenesis of these tumors in the forestomach was not disclosed, but it cannot be
excluded that they could be due to stimulation of the proliferation of the stem cell in the
border zone between the squamous epithelium and the oxyntic mucosa secondary to sub-
stances released from an increased ECLcell mass. The release from these ECLcells could
be particularly exaggerated not only due to hypergastrinemia secondary to an inhibition
ofacid secretion, butpossibly also by an attenuation ofthe histamine restraint on ECLcell
release due to the H2-receptor blocking effect ofthe drug [82]. Ifgastrin mediates the general
trophic effect on the oxyntic mucosaby stimulating the release ofhistamine and other sub-
stances with mitogenic activity (see above), it is not unlikely that gastrin could play a role
in the tumorigenesis of gastric carcinomas of intestinal type as well. There are, in fact,
observations suggesting that products from ECLcells can induce growth derangements in
nearby mucosa. Thus, the mucosa covering ECL-omas in Mastomys may show dysplasia.
The pathogenesis of hyperplastic and adenomatous polyps developing in hypergastrine-
mic patients with atrophic gastritis typeA [83] is not known, but hyperplastic polyps have
been described together with gastric carcinoma ofthe diffuse type [84], and also recently
in patients on long-term omeprazole treatment (G. Brunner, Hannover, Germany. Personal
communication). So-called collision tumors with one part ofthe tumorbeing atypical car-
cinoid while the other is a differentiated adenocarcinoma have also been described in the
oxyntic mucosa [85]. In such cases, the adenocarcinoma could be induced by the release
of paracrine mediators from the carcinoids. On the other hand, the so-called composite
gastric carcinoids and adenocarcinomas where the tumors show a mixture of carcinoid
and carcinomatous tissue at different places, the so-called adenocarcinoma part, has as a
rule been of the diffuse type [86]. In such cases the carcinoma component may only rep-
resent a further malignization of the carcinoid neuroendocrine tumor cell.
CONCLUSION
The ECL cell has a central role in the regulation ofthe function ofthe oxyntic mucosa
and may have a similarly central role in the regulation ofmucosal growth in the same area.
There is no reason to doubt that the human ECL cell, like its murine counterparts, does
have the ability to self-replication. Gastrin is the main regulator ofECL cell function and
growth. Hypergastrinemia induces ECL cell hyperplasia and ECL cell carcinoids, and
since tumorigenesis is a continuous process, this will necessarily predispose to the develop-
ment of more malignant ECL derived tumors like ECL cell neuroendocrine carcinomas
and probably some ofthe tumors presently classified as gastric carcinomas ofdiffuse type.
ECL cell-derived tumors developing in normogastrinemic individuals tend to be more
malignant than those developing in patients with hypergastrinemia, probably reflecting
gastrin independent growth in these so-called spontaneous ECL-omas. By release of its
different mediators, the ECL cell could also contribute to the tumorigenesis from the
endodermal stem cell leading to carcinomas ofintestinal type. latrogenic hypergastrinemia
should be avoided in young individuals since it would be expected to increase the fre-
quency of gastric carcinomas [87].
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